Alan Cantor

Publications

1. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41. Blood Adv. 2023 10 24; 7(20):6092-6107. View Abstract
2. Transient neonatal hemolytic anemia due to the novel gamma globin gene mutation HBG2:C.290T>C, p.Leu97Pro (hemoglobin Wareham). Pediatr Blood Cancer. 2023 01; 70(1):e30067. View Abstract
3. Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype. Blood. 2022 05 26; 139(21):3159-3165. View Abstract
4. Opening the window for endothelial-to-hematopoietic transition. Genes Dev. 2021 11 01; 35(21-22):1398-1400. View Abstract
5. The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. Haematologica. 2021 11 01; 106(11):3004-3007. View Abstract
6. B-cell acute lymphoblastic leukemia in patients with germline RUNX1 mutations. Blood Adv. 2021 08 24; 5(16):3199-3202. View Abstract
7. Familial thrombocytopenia due to a complex structural variant resulting in a WAC-ANKRD26 fusion transcript. J Exp Med. 2021 06 07; 218(6). View Abstract
8. Profound intravascular hemolysis due to clostridial sepsis in an infant with necrotizing enterocolitis. Blood. 2021 04 22; 137(16):2273. View Abstract
9. Common variants in signaling transcription-factor-binding sites drive phenotypic variability in red blood cell traits. Nat Genet. 2020 12; 52(12):1333-1345. View Abstract
10. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Neuro Oncol. 2020 10 14; 22(10):1527-1535. View Abstract
11. CHD7 and Runx1 interaction provides a braking mechanism for hematopoietic differentiation. Proc Natl Acad Sci U S A. 2020 09 22; 117(38):23626-23635. View Abstract
12. Infantile Myelofibrosis and Myeloproliferation with CDC42 Dysfunction. J Clin Immunol. 2020 05; 40(4):554-566. View Abstract
13. Role of RUNX Family Transcription Factors in DNA Damage Response. Mol Cells. 2020 Feb 29; 43(2):99-106. View Abstract
14. Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1. Ann Clin Transl Neurol. 2019 12; 6(12):2555-2565. View Abstract
15. Zfp281 (ZBP-99) plays a functionally redundant role with Zfp148 (ZBP-89) during erythroid development. Blood Adv. 2019 08 27; 3(16):2499-2511. View Abstract
16. Bone Marrow Morphology Associated With Germline RUNX1 Mutations in Patients With Familial Platelet Disorder With Associated Myeloid Malignancy. Pediatr Dev Pathol. 2019 Jul-Aug; 22(4):315-328. View Abstract
17. A home-based mentored vegetable gardening intervention demonstrates feasibility and improvements in physical activity and performance among breast cancer survivors. Cancer. 2018 08; 124(16):3427-3435. View Abstract
18. Pilot Randomized Controlled Trial of a Home Vegetable Gardening Intervention among Older Cancer Survivors Shows Feasibility, Satisfaction, and Promise in Improving Vegetable and Fruit Consumption, Reassurance of Worth, and the Trajectory of Central Adiposity. J Acad Nutr Diet. 2018 04; 118(4):689-704. View Abstract
19. Choosing wisely: RUNX1 alternate promoter use. Blood. 2017 07 20; 130(3):236-237. View Abstract
20. Erythropoietin signaling regulates heme biosynthesis. Elife. 2017 05 29; 6. View Abstract
21. Contextual factors influencing the implementation of the obstetrics hemorrhage initiative in Florida. J Perinatol. 2017 02; 37(2):150-156. View Abstract
22. Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Neurology. 2016 Dec 13; 87(24):2575-2584. View Abstract
23. RhoH participates in a multi-protein complex with the zinc finger protein kaiso that regulates both cytoskeletal structures and chemokine-induced T cells. Small GTPases. 2018 05 04; 9(3):260-273. View Abstract
24. Detailed methods of two home-based vegetable gardening intervention trials to improve diet, physical activity, and quality of life in two different populations of cancer survivors. Contemp Clin Trials. 2016 09; 50:201-12. View Abstract
25. Pregnancy and Birth Outcomes among Women with Idiopathic Thrombocytopenic Purpura. J Pregnancy. 2016; 2016:8297407. View Abstract
26. Runx1 Phosphorylation by Src Increases Trans-activation via Augmented Stability, Reduced Histone Deacetylase (HDAC) Binding, and Increased DNA Affinity, and Activated Runx1 Favors Granulopoiesis. J Biol Chem. 2016 Jan 08; 291(2):826-36. View Abstract
27. Utility of Wood's light in margin determination of melanoma in situ after excisional biopsy. Dermatol Surg. 2015 May; 41(5):572-8. View Abstract
28. The mTORC1/4E-BP pathway coordinates hemoglobin production with L-leucine availability. Sci Signal. 2015 Apr 14; 8(372):ra34. View Abstract
29. Bmi1 promotes erythroid development through regulating ribosome biogenesis. Stem Cells. 2015 Mar; 33(3):925-38. View Abstract
30. Myeloid Proliferations Associated with Down Syndrome. J Hematop. 2015 Sep; 8(3):169-176. View Abstract
31. Tanning accelerators: prevalence, predictors of use, and adverse effects. J Am Acad Dermatol. 2015 Jan; 72(1):99-104. View Abstract
32. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol. 2015 Apr; 17(4):596-603. View Abstract
33. TMEM14C is required for erythroid mitochondrial heme metabolism. J Clin Invest. 2014 Oct; 124(10):4294-304. View Abstract
34. Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters. J Neurooncol. 2014 Nov; 120(2):361-70. View Abstract
35. Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017. Ann Surg Oncol. 2015 Jan; 22(1):75-81. View Abstract
36. Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study. Pediatr Blood Cancer. 2014 Jun; 61(6):982-6. View Abstract
37. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther. 2014 May; 22(5):1048-55. View Abstract
38. Developmental differences in IFN signaling affect GATA1s-induced megakaryocyte hyperproliferation. J Clin Invest. 2013 Jul 01. View Abstract
39. Prognostic relevance of cytochrome C oxidase in primary glioblastoma multiforme. PLoS One. 2013; 8(4):e61035. View Abstract
40. Harvest for health gardening intervention feasibility study in cancer survivors. Acta Oncol. 2013 Aug; 52(6):1110-8. View Abstract
41. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer. 2013 May 15; 119(10):1776-83. View Abstract
42. Preclinical evaluation of oncolytic d?(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastases. Int J Breast Cancer. 2012; 2012:628697. View Abstract
43. The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. J Urol. 2013 Feb; 189(2):486-92. View Abstract
44. Dynamin 3 and platelet size variation. Blood. 2012 Dec 06; 120(24):4666-7. View Abstract
45. Relationships among participant international prostate symptom score, benign prostatic hyperplasia impact index changes and global ratings of change in a trial of phytotherapy in men with lower urinary tract symptoms. J Urol. 2013 Mar; 189(3):987-92. View Abstract
46. A Src family kinase-Shp2 axis controls RUNX1 activity in megakaryocyte and T-lymphocyte differentiation. Genes Dev. 2012 Jul 15; 26(14):1587-601. View Abstract
47. Death-defying apoptotic caspases in thrombopoiesis. Blood. 2012 May 03; 119(18):4098-9. View Abstract
48. Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors. Mol Cell. 2012 Feb 10; 45(3):330-43. View Abstract
49. Megakaryopoiesis and thrombopoiesis: an update on cytokines and lineage surface markers. Methods Mol Biol. 2012; 788:291-303. View Abstract
50. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA. 2011 Sep 28; 306(12):1344-51. View Abstract
51. Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy. Clin Breast Cancer. 2011 Oct; 11(5):312-9. View Abstract
52. Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields. Br J Cancer. 2011 Aug 23; 105(5):640-8. View Abstract
53. Role of ZBP-89 in human globin gene regulation and erythroid differentiation. Blood. 2011 Sep 29; 118(13):3684-93. View Abstract
54. Gene expression analysis in radiotherapy patients and C57BL/6 mice as a measure of exposure to ionizing radiation. Radiat Res. 2011 Jul; 176(1):49-61. View Abstract
55. Identification of distal cis-regulatory elements at mouse mitoferrin loci using zebrafish transgenesis. Mol Cell Biol. 2011 Apr; 31(7):1344-56. View Abstract
56. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell. 2010 Oct 15; 143(2):313-24. View Abstract
57. Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer. Lung Cancer. 2011 May; 72(2):219-23. View Abstract
58. TIF1gamma controls erythroid cell fate by regulating transcription elongation. Cell. 2010 Jul 09; 142(1):133-43. View Abstract
59. Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome. Clin Cancer Res. 2010 May 15; 16(10):2890-8. View Abstract
60. Insights into GATA-1-mediated gene activation versus repression via genome-wide chromatin occupancy analysis. Mol Cell. 2009 Nov 25; 36(4):682-95. View Abstract
61. The role and regulation of friend of GATA-1 (FOG-1) during blood development in the zebrafish. Blood. 2009 Nov 19; 114(21):4654-63. View Abstract
62. Common features of megakaryocytes and hematopoietic stem cells: what's the connection? J Cell Biochem. 2009 Aug 01; 107(5):857-64. View Abstract
63. Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. Mol Cell Biol. 2009 Aug; 29(15):4103-15. View Abstract
64. Use of in vivo biotinylation to study protein-protein and protein-DNA interactions in mouse embryonic stem cells. Nat Protoc. 2009; 4(4):506-17. View Abstract
65. Tandem affinity purification of protein complexes in mouse embryonic stem cells using in vivo biotinylation. Curr Protoc Stem Cell Biol. 2009 Mar; Chapter 1:Unit1B.5. View Abstract
66. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008 Dec 19; 322(5909):1839-42. View Abstract
67. TLX1 (HOX11) immortalization of embryonic stem cell-derived and primary murine hematopoietic progenitors. Curr Protoc Stem Cell Biol. 2008 Dec; Chapter 1:Unit 1F.7. View Abstract
68. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol. 2008 Oct; 3(10):1112-8. View Abstract
69. Antagonism of FOG-1 and GATA factors in fate choice for the mast cell lineage. J Exp Med. 2008 Mar 17; 205(3):611-24. View Abstract
70. Identification of ZBP-89 as a novel GATA-1-associated transcription factor involved in megakaryocytic and erythroid development. Mol Cell Biol. 2008 Apr; 28(8):2675-89. View Abstract
71. Immune responses to guided imagery during breast cancer treatment. Biol Res Nurs. 2008 Jan; 9(3):205-14. View Abstract
72. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J Immunother. 2008 Jan; 31(1):72-80. View Abstract
73. Expression of TGFbeta type-II receptor in association with markers of proliferation and apoptosis in premalignant lung lesions. Cancer. 2007 Oct 01; 110(7):1527-31. View Abstract
74. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2007 Jul 01; 25(19):2741-6. View Abstract
75. Friend of GATA-1-independent transcriptional repression: a novel mode of GATA-1 function. Blood. 2007 Jun 15; 109(12):5230-3. View Abstract
76. Loss of nuclear p21(Cip1/WAF1) during neoplastic progression to metastasis in gamma-irradiated p21 hemizygous mice. Exp Mol Pathol. 2007 Jun; 82(3):234-44. View Abstract
77. Improved survival in BRCA2 carriers with ovarian cancer. Fam Cancer. 2007; 6(1):113-9. View Abstract
78. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Ann Surg Oncol. 2007 Feb; 14(2):869-84. View Abstract
79. A dosimetric analysis of unstranded seeds versus customized stranded seeds in transperineal interstitial permanent prostate seed brachytherapy. Brachytherapy. 2006 Oct-Dec; 5(4):244-50. View Abstract
80. Paget's disease in the era of sentinel lymph node biopsy. Am J Surg. 2006 Oct; 192(4):481-3. View Abstract
81. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol. 2006 Oct 10; 24(29):4731-7. View Abstract
82. Treatment of intermediate-risk prostate cancer with brachytherapy without supplemental pelvic radiotherapy: a review of the H. Lee Moffitt Cancer Center experience. Urol Oncol. 2006 Sep-Oct; 24(5):384-90. View Abstract
83. Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial. Mol Cancer Ther. 2006 Aug; 5(8):2130-7. View Abstract
84. Survival after surgical resection of isolated pulmonary metastases from malignant melanoma. Cancer Control. 2006 Jul; 13(3):218-23. View Abstract
85. Prospective evaluation of RRM1 as a predictor of response to gemcitabine/carboplatin (GC) in non-small cell lung cancer (NSCLC). J Clin Oncol. 2006 Jun 20; 24(18_suppl):7054. View Abstract
86. The benefits of a restaging PET scan after two cycles of neoadjuvant chemotherapy for resectable non-small cell lung cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):17092. View Abstract
87. Fatigue is a cause of functional dependence in older cancer survivors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):8538. View Abstract
88. beta2 Integrins are characteristically absent in acute promyelocytic leukemia and rapidly upregulated in vivo upon differentiation with all-trans retinoic acid. Leuk Res. 2007 Jan; 31(1):49-57. View Abstract
89. A complication-free course ensures a survival advantage in patients after regional therapy for metastatic colorectal cancer. Am Surg. 2006 Jun; 72(6):505-10. View Abstract
90. Survival outcomes in node-negative breast cancer patients evaluated with complete axillary node dissection versus sentinel lymph node biopsy. Ann Surg Oncol. 2006 May; 13(5):708-11. View Abstract
91. A global genome damage score predictive of lung cancer patients outcome. Oncogene. 2006 Jul 27; 25(32):4491-4. View Abstract
92. Pulmonary embolism after major abdominal surgery in gynecologic oncology. Obstet Gynecol. 2006 Mar; 107(3):666-71. View Abstract
93. Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies. Clin Cancer Res. 2006 Jan 15; 12(2):523-8. View Abstract
94. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res. 2006 Jan 01; 12(1):20-8. View Abstract
95. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control. 2006 Jan; 13(1):72-8. View Abstract
96. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005 Dec 15; 104(12):2807-16. View Abstract
97. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res. 2005 Dec 01; 11(23):8288-94. View Abstract
98. Burnout in clinical research coordinators in the United States. Oncol Nurs Forum. 2005 Nov 03; 32(6):1123-30. View Abstract
99. Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancer. Chest. 2005 Nov; 128(5):3467-74. View Abstract
100. Treatment decision-making strategies and influences in patients with localized prostate carcinoma. Cancer. 2005 Oct 01; 104(7):1381-90. View Abstract
101. Prediction of radiation sensitivity using a gene expression classifier. Cancer Res. 2005 Aug 15; 65(16):7169-76. View Abstract
102. The efficacy and safety of pain management before and after implementation of hospital-wide pain management standards: is patient safety compromised by treatment based solely on numerical pain ratings? Anesth Analg. 2005 Aug; 101(2):474-480. View Abstract
103. Diagnosing pulmonary embolism: experience with spiral CT pulmonary angiography in gynecologic oncology. Gynecol Oncol. 2005 Aug; 98(2):289-93. View Abstract
104. A case-control study evaluating the association of purposeful physical activity, body fat distribution, and steroid hormones on premenopausal breast cancer risk. Breast J. 2005 Jul-Aug; 11(4):266-72. View Abstract
105. GATA transcription factors in hematologic disease. Int J Hematol. 2005 Jun; 81(5):378-84. View Abstract
106. Phase I/II study of atrasentan (A) in combination with carboplatin (C) and paclitaxel (P) in chemonaive patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2005 Jun; 23(16_suppl):7105. View Abstract
107. Small tumor size and limited smoking history predicts activated EGFR-Stat3 in early stage non-small cell lung cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):7075. View Abstract
108. Phase II study of induction chemotherapy with gemcitabine and carboplatin (IndGC) followed by paclitaxel and carboplatin with concurrent thoracic radiation (PCRT) for patients with unresectable stage III non-small-cell lung cancer (NSCLC): MCC-13240. J Clin Oncol. 2005 Jun; 23(16_suppl):7307. View Abstract
109. Phase II study of neoadjuvant chemotherapy with gemicitabine and pemetrexed (NeoGP) in resectable non-small-cell lung cancer (NSCLC): MCC 13726. J Clin Oncol. 2005 Jun; 23(16_suppl):7314. View Abstract
110. Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small-cell lung cancer (NSCLC). J Clin Oncol. 2005 Jun; 23(16_suppl):7277. View Abstract
111. Influence of concomitant medications on toxicity from chemotherapy in elderly patients. Focus on cytochrome P-450 inhibition and protein binding effects. J Clin Oncol. 2005 Jun; 23(16_suppl):8025. View Abstract
112. Global genome damage is predictive of cancer patients' outcome. J Clin Oncol. 2005 Jun; 23(16_suppl):9542. View Abstract
113. The incidence of pulmonary embolism after gynecologic oncologic surgery. J Clin Oncol. 2005 Jun; 23(16_suppl):5089. View Abstract
114. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol. 2005 May 20; 23(15):3526-35. View Abstract
115. Differences in Smad4 expression in human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck squamous cell carcinoma. Clin Cancer Res. 2005 May 01; 11(9):3191-7. View Abstract
116. EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer. J Clin Oncol. 2005 Mar 20; 23(9):1921-6. View Abstract
117. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 2005 Mar; 127(3):978-83. View Abstract
118. Accuracy of intraoperative imprint cytology for sentinel lymph node evaluation in the treatment of breast carcinoma. Cancer. 2005 Feb 25; 105(1):13-20. View Abstract
119. Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA. 2005 Feb 23; 293(8):970-8. View Abstract
120. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer. 2005 Feb; 47(2):183-92. View Abstract
121. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice. Brachytherapy. 2005; 4(1):34-44. View Abstract
122. Coregulation of GATA factors by the Friend of GATA (FOG) family of multitype zinc finger proteins. Semin Cell Dev Biol. 2005 Feb; 16(1):117-28. View Abstract
123. Efficacy and cost-effectiveness of a minimal intervention to prevent smoking relapse: dismantling the effects of amount of content versus contact. J Consult Clin Psychol. 2004 Oct; 72(5):797-808. View Abstract
124. Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest. 2004 Aug; 126(2):347-51. View Abstract
125. Validation of RRM1 and PTEN as prognostic parameters of outcome in non-small cell lung cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):7154. View Abstract
126. Predictive utility of RRM1 promoter polymorphisms on outcome of patients with non-small cell lung cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):7155. View Abstract
127. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2004 Jul; 13(7):1185-91. View Abstract
128. A randomized controlled trial to increase cancer screening among attendees of community health centers. Ann Fam Med. 2004 Jul-Aug; 2(4):294-300. View Abstract
129. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol. 2004 May 15; 22(10):1878-85. View Abstract
130. Colorectal cancer screening among a sample of community health center attendees. J Health Care Poor Underserved. 2004 May; 15(2):281-93. View Abstract
131. The specific role of isoflavones in reducing prostate cancer risk. Prostate. 2004 May 01; 59(2):141-7. View Abstract
132. A multi-institutional study of orthotopic neobladders: functional results in men and women. BJU Int. 2004 Apr; 93(6):803-6. View Abstract
133. Role of p53, CD44V6 and CD57 in differentiating between benign and malignant follicular neoplasms of the thyroid. In Vivo. 2004 Mar-Apr; 18(2):189-95. View Abstract
134. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 2004 May 01; 103(9):3271-7. View Abstract
135. Coregulator-dependent facilitation of chromatin occupancy by GATA-1. Proc Natl Acad Sci U S A. 2004 Jan 27; 101(4):980-5. View Abstract
136. Fatigue, weight gain, lethargy and amenorrhea in breast cancer patients on chemotherapy: is subclinical hypothyroidism the culprit? Breast Cancer Res Treat. 2004 Jan; 83(2):149-59. View Abstract
137. Osteopontin identified as colon cancer tumor progression marker. C R Biol. 2003 Oct-Nov; 326(10-11):1041-3. View Abstract
138. The importance of preservation of the ethical principle of equipoise in the design of clinical trials: relative impact of the methodological quality domains on the treatment effect in randomized controlled trials. Account Res. 2003 Oct-Dec; 10(4):301-15. View Abstract
139. The therapeutic effects of epidural intercellular adhesion molecule-1 monoclonal antibody in a rabbit model: involvement of the intercellular adhesion molecule-1 pathway in spinal cord ischemia. Anesth Analg. 2003 Sep; 97(3):857-862. View Abstract
140. Comparative outcomes analysis of procedures performed in physician offices and ambulatory surgery centers. Arch Surg. 2003 Sep; 138(9):991-5. View Abstract
141. GATA-1 converts lymphoid and myelomonocytic progenitors into the megakaryocyte/erythrocyte lineages. Immunity. 2003 Sep; 19(3):451-62. View Abstract
142. Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution. Cancer Control. 2003 Sep-Oct; 10(5):388-95. View Abstract
143. Are older French patients as willing as older American patients to undertake chemotherapy? J Clin Oncol. 2003 Sep 01; 21(17):3214-9. View Abstract
144. p21Cip1 nullizygosity increases tumor metastasis in irradiated mice. Cancer Res. 2003 Jun 15; 63(12):3021-5. View Abstract
145. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer. 2003 Jun; 40(3):267-79. View Abstract
146. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 2003 Mar 15; 63(6):1270-9. View Abstract
147. Can older cancer patients tolerate chemotherapy? A prospective pilot study. Cancer. 2003 Feb 15; 97(4):1107-14. View Abstract
148. Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models. Oncogene. 2002 Dec 05; 21(55):8486-97. View Abstract
149. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002 Nov 15; 62(22):6659-66. View Abstract
150. Completion axillary lymph node dissection minimizes the likelihood of false negatives for patients with invasive breast carcinoma and cytokeratin positive only sentinel lymph nodes. Am J Surg. 2002 Oct; 184(4):302-6. View Abstract
151. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer. 2002 Sep 10; 101(2):151-5. View Abstract
152. Indirect economic effects of long-term breast cancer survival. Cancer Pract. 2002 Sep-Oct; 10(5):248-55. View Abstract
153. Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study. Eur J Cancer. 2002 Jul; 38(11):1466-73. View Abstract
154. GATA-factor dependence of the multitype zinc-finger protein FOG-1 for its essential role in megakaryopoiesis. Proc Natl Acad Sci U S A. 2002 Jul 09; 99(14):9237-42. View Abstract
155. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med. 2002 Jun 03; 195(11):1387-95. View Abstract
156. Brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer. Curr Urol Rep. 2002 Jun; 3(3):250-7. View Abstract
157. Distinct domains of the GATA-1 cofactor FOG-1 differentially influence erythroid versus megakaryocytic maturation. Mol Cell Biol. 2002 Jun; 22(12):4268-79. View Abstract
158. Transcriptional regulation of erythropoiesis: an affair involving multiple partners. Oncogene. 2002 May 13; 21(21):3368-76. View Abstract
159. Interaction between FOG-1 and the corepressor C-terminal binding protein is dispensable for normal erythropoiesis in vivo. Mol Cell Biol. 2002 May; 22(9):3121-8. View Abstract
160. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol. 2002 May; 167(5):1995-2000. View Abstract
161. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst. 2002 Apr 03; 94(7):513-21. View Abstract
162. Fatal disseminated Candida lusitaniae infection in an infant with chronic granulomatous disease. Pediatr Infect Dis J. 2002 Mar; 21(3):262-4. View Abstract
163. Age and body mass index may increase the chance of failure in sentinel lymph node biopsy for women with breast cancer. Breast J. 2002 Mar-Apr; 8(2):88-91. View Abstract
164. The specific role of isoflavones on estrogen metabolism in premenopausal women. Cancer. 2002 Feb 15; 94(4):1166-74. View Abstract
165. Expression of early lung cancer detection marker: hnRNP-A2/B1 and its relation to microsatellite alteration in non-small cell lung cancer. Lung Cancer. 2001 Dec; 34(3):341-50. View Abstract
166. Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis. J Am Coll Surg. 2001 Dec; 193(6):593-600. View Abstract
167. Hematopoietic development: a balancing act. Curr Opin Genet Dev. 2001 Oct; 11(5):513-9. View Abstract
168. The relationship between age and the fatty acid composition of cerebral cortex and erythrocytes in human subjects. Brain Res Bull. 2001 Sep 15; 56(2):79-85. View Abstract
169. Projecting the standard error of the Kaplan-Meier estimator. Stat Med. 2001 Jul 30; 20(14):2091-7. View Abstract
170. Effect of fractionated regional external beam radiotherapy on peripheral blood cell count. Int J Radiat Oncol Biol Phys. 2001 Jun 01; 50(2):465-72. View Abstract
171. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Arch Surg. 2001 Jun; 136(6):688-92. View Abstract
172. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg. 2001 Jun; 67(6):513-9; discussion 519-21. View Abstract
173. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas. J Am Acad Dermatol. 2001 May; 44(5):762-6. View Abstract
174. Learning curves and breast cancer lymphatic mapping: institutional volume index. J Surg Res. 2001 May 01; 97(1):92-6. View Abstract
175. Does prosthetic covering of nitinol stents alter healing characteristics or hemodynamics? J Endovasc Ther. 2000 Dec; 7(6):469-78. View Abstract
176. Loss of p21WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model. Oncogene. 2000 Nov 09; 19(47):5338-47. View Abstract
177. Risk factors associated with hypothyroidism after laryngectomy. Otolaryngol Head Neck Surg. 2000 Sep; 123(3):211-7. View Abstract
178. The uncertainty principle and industry-sponsored research. Lancet. 2000 Aug 19; 356(9230):635-8. View Abstract
179. Prognostic factors in malignant gastrointestinal stromal tumors. Ann Clin Lab Sci. 2000 Jul; 30(3):239-47. View Abstract
180. Android obesity at diagnosis and breast carcinoma survival: Evaluation of the effects of anthropometric variables at diagnosis, including body composition and body fat distribution and weight gain during life span,and survival from breast carcinoma. Cancer. 2000 Jun 15; 88(12):2751-7. View Abstract
181. Do cytokeratin-positive-only sentinel lymph nodes warrant complete axillary lymph node dissection in patients with invasive breast cancer? Am Surg. 2000 Jun; 66(6):574-8. View Abstract
182. Evolution of techniques for ultrasound-guided palladium 103 brachytherapy in 950 patients with prostate cancer. Tech Urol. 2000 Jun; 6(2):128-34. View Abstract
183. Clonal variability in CD95 expression is the major determinant in Fas-medicated, but not chemotherapy-medicated apoptosis in the RPMI 8226 multiple myeloma cell line. Leukemia. 2000 May; 14(5):830-40. View Abstract
184. Minimally invasive treatment for localized adenocarcinoma of the prostate: review of 1048 patients treated with ultrasound-guided palladium-103 brachytherapy. J Endourol. 2000 May; 14(4):343-50. View Abstract
185. Differential diagnosis of endometrial hyperplasia and carcinoma by computerized image cytometry of cell proliferation, apoptosis and Bcl-2 expression. Ann Clin Lab Sci. 1999 Oct-Dec; 29(4):308-15. View Abstract
186. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma of the lower extremity. Plast Reconstr Surg. 1999 Sep; 104(4):964-9. View Abstract
187. Different sequence requirements for expression in erythroid and megakaryocytic cells within a regulatory element upstream of the GATA-1 gene. Development. 1999 Jun; 126(12):2799-811. View Abstract
188. Predictability of PSA failure in prostate cancer by computerized cytometric assessment of tumoral cell proliferation. Urology. 1999 May; 53(5):931-8. View Abstract
189. FOG-2: A novel GATA-family cofactor related to multitype zinc-finger proteins Friend of GATA-1 and U-shaped. Proc Natl Acad Sci U S A. 1999 Feb 02; 96(3):950-5. View Abstract
190. Surgical and endovascular intervention for infrainguinal vein graft stenosis. J Vasc Surg. 1999 Jan; 29(1):60-70; discussion 70-1. View Abstract
191. Ischemia detection in women: the diagnostic value of exercise QRS duration changes. J Electrocardiol. 1998 Oct; 31(4):271-7. View Abstract
192. Review and evaluation of MRI nonuniformity corrections for brain tumor response measurements. Med Phys. 1998 Sep; 25(9):1655-66. View Abstract
193. Development of a head and neck companion module for the quality of life-radiation therapy instrument (QOL-RTI) Int J Radiat Oncol Biol Phys. 1998 Sep 01; 42(2):257-61. View Abstract
194. CD44V6 expression in human colorectal carcinoma. Hum Pathol. 1998 Jun; 29(6):627-35. View Abstract
195. Efficacy of hyperthermic isolated limb perfusion for extremity-confined recurrent melanoma. Ann Surg Oncol. 1998 Jun; 5(4):376-83. View Abstract
196. Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients. Urology. 1998 May; 51(5):796-803. View Abstract
197. Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: a Pediatric Oncology Group study. Med Pediatr Oncol. 1998 Apr; 30(4):201-9. View Abstract
198. Postoperative accelerated radiotherapy in high-risk squamous cell carcinoma of the head and neck: long-term results of a prospective trial. Head Neck. 1998 Mar; 20(2):119-23. View Abstract
199. Ischemia detection after myocardial infarction: diagnostic value of exercise-induced QRS duration changes evaluated by a new computerized method. J Electrocardiol. 1998 Jan; 31(1):9-15. View Abstract
200. QRS prolongation measured by a new computerized method: a sensitive marker for detecting exercise-induced ischemia. Cardiology. 1997 Sep-Oct; 88(5):446-52. View Abstract
201. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol. 1997 Aug; 15(8):2769-79. View Abstract
202. Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact? Breast Cancer Res Treat. 1997 Jun; 44(2):135-43. View Abstract
203. Bilaterality and recurrence rates for lobular breast cancer: considerations for treatment. Ann Surg Oncol. 1997 Apr-May; 4(3):198-202. View Abstract
204. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis. 1997 Apr; 24(4):635-42. View Abstract
205. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst. 1997 Mar 05; 89(5):373-80. View Abstract
206. Florida's undeclared epidemic: malignant melanoma. J Fla Med Assoc. 1997 Mar; 84(3):161-5. View Abstract
207. Spot urine osmolality, age and bladder capacity as predictors of response to desmopressin in nocturnal enuresis. Scand J Urol Nephrol Suppl. 1997; 183:41-5. View Abstract
208. Multiple primary melanomas: implications for screening and follow-up programs for melanoma. Ann Surg Oncol. 1997 Jan; 4(1):19-23. View Abstract
209. Chemotherapy for patients with recurrent or refractory neuroblastoma: a POG Phase II study. J Pediatr Hematol Oncol. 1997 Jan-Feb; 19(1):62-7. View Abstract
210. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA. 1996 Dec 11; 276(22):1818-22. View Abstract
211. Peptide amidating activity in human bronchoalveolar lavage fluid. Lung Cancer. 1996 Jun; 14(2-3):239-51. View Abstract
212. Modified histologic grading of neuroblastomas by replacement of mitotic rate with mitosis karyorrhexis index. A clinicopathologic study of 223 cases from the Pediatric Oncology Group. Cancer. 1996 Apr 15; 77(8):1582-8. View Abstract
213. Power calculation for the log rank test using historical data. Control Clin Trials. 1996 Apr; 17(2):111-6. View Abstract
214. Age and family relationship accentuate the risk of insulin-dependent diabetes mellitus (IDDM) in relatives of patients with IDDM. J Clin Endocrinol Metab. 1995 Dec; 80(12):3739-43. View Abstract
215. Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg. 1995 Oct; 222(4):549-59; discussion 559-61. View Abstract
216. Nonrhabdomyosarcomatous soft tissue sarcomas of childhood: formulation of a simplified system for grading. Mod Pathol. 1995 Sep; 8(7):705-10. View Abstract
217. A test of the association of a time-dependent state variable to survival. Comput Methods Programs Biomed. 1995 Feb; 46(2):101-5. View Abstract
218. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol. 1995 Feb; 24(2):87-92. View Abstract
219. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1994 Aug; 12(8):1616-20. View Abstract
220. The role of prognostic factors in treatment selection for early-stage Hodgkin's disease. Am J Clin Oncol. 1994 Jun; 17(3):189-95. View Abstract
221. A modified isometric test to evaluate blood pressure control with once-daily slow-release verapamil. S Afr Med J. 1993 Nov; 83(11):840-2. View Abstract
222. Correlation between morphologic and other prognostic markers of neuroblastoma. A study of histologic grade, DNA index, N-myc gene copy number, and lactic dehydrogenase in patients in the Pediatric Oncology Group. Cancer. 1993 May 15; 71(10):3173-81. View Abstract
223. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med. 1993 Mar 25; 328(12):847-54. View Abstract
224. Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1993 Jan; 11(1):96-9. View Abstract
225. Lysosomal enzyme phosphorylation. II. Protein recognition determinants in either lobe of procathepsin D are sufficient for phosphorylation of both the amino and carboxyl lobe oligosaccharides. J Biol Chem. 1992 Nov 15; 267(32):23349-56. View Abstract
226. Lysosomal enzyme phosphorylation. I. Protein recognition determinants in both lobes of procathepsin D mediate its interaction with UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase. J Biol Chem. 1992 Nov 15; 267(32):23342-8. View Abstract
227. Phosphorylation of Asn-linked oligosaccharides located at novel sites on the lysosomal enzyme cathepsin D. J Biol Chem. 1992 Nov 15; 267(32):23357-63. View Abstract
228. A method for [3H]mannose labeling of Asn-linked oligosaccharides on recombinant glycoproteins synthesized in Xenopus oocytes. Anal Biochem. 1992 Sep; 205(2):220-6. View Abstract
229. Recommendations for modification of terminology of neuroblastic tumors and prognostic significance of Shimada classification. A clinicopathologic study of 213 cases from the Pediatric Oncology Group. Cancer. 1992 Apr 15; 69(8):2183-96. View Abstract
230. Age-linked prognostic categorization based on a new histologic grading system of neuroblastomas. A clinicopathologic study of 211 cases from the Pediatric Oncology Group. Cancer. 1992 Apr 15; 69(8):2197-211. View Abstract
231. Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res. 1992 Apr 01; 52(7):1780-5. View Abstract
232. Gallium-67 scans as an adjunct to computed tomography scans for the assessment of a residual mediastinal mass in pediatric patients with Hodgkin's disease. A Pediatric Oncology Group study. Cancer. 1991 Dec 01; 68(11):2478-80. View Abstract
233. CD5+ B lymphocytes in high-risk islet cell antibody-positive and newly diagnosed IDDM subjects. Diabetes. 1991 Oct; 40(10):1314-8. View Abstract
234. Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol. 1991 Sep; 9(9):1591-8. View Abstract
235. The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma. J Clin Oncol. 1991 Jun; 9(6):1045-9. View Abstract
236. Comparative effectiveness of two combined modality regimens in the treatment of surgical stage III Hodgkin's disease in children. An 8-year follow-up study by the Pediatric Oncology Group. Am J Pediatr Hematol Oncol. 1991; 13(4):450-8. View Abstract
237. Widowhood, sexuality and aging: a life span analysis. J Sex Marital Ther. 1988; 14(1):49-62. View Abstract
238. Recognition site directing vitamin K-dependent gamma-carboxylation resides on the propeptide of factor IX. Cell. 1987 Jan 30; 48(2):185-91. View Abstract
239. The course of pregnancy in patients with artificial heart valves treated with dipyridamole. Int J Gynaecol Obstet. 1980 Sep-Oct; 18(2):128-32. View Abstract
240. The Coagulation and Sterilization of Culture Media. J Bacteriol. 1943 Aug; 46(2):203-4. View Abstract
241. A Microscopic Alkali-Solubility Test for the Identification of Gonococcus Colonies. J Bacteriol. 1942 Aug; 44(2):237-40. View Abstract
Show All Publications Show Fewer Publications